A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome.
Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients.
Blaszyk
H
H
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
Hartmann
A
A
Cunningham
J M
JM
Schaid
D
D
Wold
L E
LE
Kovach
J S
JS
Sommer
S S
SS
D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D015331:Cohort Studies; D005500:Follow-Up Studies; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D009154:Mutation; D011379:Prognosis; D011446:Prospective Studies